Nang Kuang Pharmaceutical Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 1752?
Owner Type	Number of Shares	Ownership Percentage
Institutions	1,163,039	1.15%
Individual Insiders	17,204,102	17%
Private Companies	33,195,735	32.9%
General Public	49,426,124	48.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 12 shareholders own 51.06% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
19.8%	Zhengzhao Investment Co., Ltd.	20,014,220	NT$823.6m	0%	no data
6.24%	Ben-Sung Chen	6,297,334	NT$259.1m	0%	no data
5.01%	Ben-Chung Chen	5,057,157	NT$208.1m	0%	no data
3.94%	Song-ban Investment Co., Ltd.	3,978,517	NT$163.7m	0%	no data
3.49%	Yu-Bei Wang	3,525,943	NT$145.1m	0%	no data
3.39%	Li Kuang Investment Co., Ltd.	3,425,176	NT$140.9m	0%	no data
2.97%	Cheng Long Investment Co., Ltd.	2,998,952	NT$123.4m	0%	no data
2.75%	Yiguang Investment Co., Ltd.	2,778,870	NT$114.4m	0%	no data
2.26%	Lixian Chen	2,278,668	NT$93.8m	0%	no data
1.07%	Dimensional Fund Advisors LP	1,084,039	NT$44.6m	0.74%	no data
0.078%	American Century Investment Management Inc	79,000	NT$3.3m	0%	no data
0.045%	Chi-Long Lin	45,000	NT$1.9m	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/31 21:08
End of Day Share Price	2024/12/31 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nang Kuang Pharmaceutical Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Zhennan Lee	Jih Sun Securities Investment Consulting Co., Ltd.
Yuan Lu	KGI Securities Co. Ltd.
Xiaowei Huang	Masterlink Securities Corp.